Lupin And Natco Receive USFDA Approval for Eribulin Injection; Shares Slip 0.23%

Mumbai, June 03: Lupin and its alliance partner Natco Pharma have received approval from the U.S. Food and Drug Administration (FDA) for Eribulin Mesylate Injection.

The approval covers Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, according to a regulatory filing submitted on Wednesday.

The product is the bioequivalent version of Halaven Injection of Eisai Inc., a branded therapy used in oncology treatment. Eribulin Mesylate Injection is indicated for patients with metastatic breast cancer who have previously undergone at least two chemotherapy regimens and for patients with unresectable or metastatic liposarcoma who have received prior anthracycline-containing therapy.

According to the company, the reference product recorded estimated annual sales of $43.7 million in the United States for the period ending April 2026, citing IQVIA data.

The approval strengthens Lupin’s U.S. generics portfolio and expands its presence in the oncology segment, a key focus area for specialty pharmaceutical companies.

Stock Market Snapshot

Despite the regulatory milestone, Lupin shares traded slightly lower during the morning session.

As of 11:17 AM IST on June 3, 2026, the stock was trading at ₹2,244.70, down 0.23% or ₹5.10 from the previous close of ₹2,249.80.

The Lupin share price remained volatile during the session, moving between ₹2,235.00 and ₹2,253.90. Market participants appeared to balance the positive impact of the FDA approval against broader sector and market movements.

Investors generally view U.S. regulatory approvals favourably as they create opportunities for new product launches and additional revenue streams in the highly competitive generics market.

Company Background

Lupin is one of India’s largest pharmaceutical companies, with operations spanning branded and generic formulations, biotechnology products and active pharmaceutical ingredients.

The company markets products in more than 100 countries and maintains a significant presence in the United States, India and other major pharmaceutical markets. Its therapeutic focus areas include respiratory, cardiovascular, diabetes, anti-infectives, gastroenterology and central nervous system disorders.

Lupin operates 15 manufacturing facilities and seven research centres globally, supporting its product development and regulatory pipeline.

Conclusion

The U.S. FDA approval for Eribulin Mesylate Injection marks another addition to Lupin’s expanding portfolio of complex generic products in partnership with Natco Pharma.

While the stock traded marginally lower following the announcement, the approval enhances Lupin’s oncology offering and provides access to a U.S. market estimated at $43.7 million annually. Investors are likely to monitor the commercial launch timeline and future regulatory approvals as indicators of growth in the company’s U.S. business.

Source:

• https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited
• https://nsearchives.nseindia.com/corporate/Lupin2_03062026105650_SELetterPressRelease.pdf